



저작자표시-비영리-변경금지 2.0 대한민국

이용자는 아래의 조건을 따르는 경우에 한하여 자유롭게

- 이 저작물을 복제, 배포, 전송, 전시, 공연 및 방송할 수 있습니다.

다음과 같은 조건을 따라야 합니다:



저작자표시. 귀하는 원저작자를 표시하여야 합니다.



비영리. 귀하는 이 저작물을 영리 목적으로 이용할 수 없습니다.



변경금지. 귀하는 이 저작물을 개작, 변형 또는 가공할 수 없습니다.

- 귀하는, 이 저작물의 재이용이나 배포의 경우, 이 저작물에 적용된 이용허락조건을 명확하게 나타내어야 합니다.
- 저작권자로부터 별도의 허가를 받으면 이러한 조건들은 적용되지 않습니다.

저작권법에 따른 이용자의 권리는 위의 내용에 의하여 영향을 받지 않습니다.

이것은 [이용허락규약\(Legal Code\)](#)을 이해하기 쉽게 요약한 것입니다.

[Disclaimer](#)

**The Effects of Vitamin D and Sarcopenia
on Bone Mineral Density in Korean women**

by

Myat Kyi La Thein

Major in Family Medicine

**Department of Family Practice and Community Health
Graduate School of Medicine, Ajou University**

**The effects of Vitamin D and Sarcopenia on
Bone Mineral Density
in Korean woman**

by

Myat Kyi La Thein

**A dissertation submitted to The Graduate School of Medicine
Ajou University
in Fulfillment of the Requirements for the Degree of
Master of Family Medicine**

Supervised by

BomTaeck Kim MD. PhD.

**Department of Family Practice and Community Health
The Graduate School of Medicine, Ajou University**

May, 2013

**This certifies that the dissertation of
Myat Kyi La Thein is approved**

SUPERVISORY COMMITTEE

BOM TAECK KIM MD.PhD. _____

JAE HONG AHN MD.PhD _____

IL JOONG PARK MD.PhD _____

ABSTRACT

An osteoporotic fracture has become a global health issue that causes tremendous impact on mortality as well as heavy socioeconomic burden. Previous studies suggested that vitamin D may prevent fractures by improving muscle mass as well as via increasing bone density directly. The purpose of the study is to determine that the influence of vitamin D on bone mineral density depends on its effects on muscle mass.

We analyzed the data from Korean National Health and Nutritional Survey IV in 2009. Women older than age 20 were included for the analyses. Bone mineral density and muscle mass were measured by DXA. Serum vitamin D concentration was tested.

Vitamin D and muscle mass affected BMD at proximal femur, but not at lumbar spine. Vitamin D deficiency and sarcopenia increased odd ratio for osteoporosis before and after adjusted for multiple variables. The effects of vitamin D deficiency on BMD still remained significant after adjustment for sarcopenia, which was vice versa.

Though vitamin D deficiency and sarcopenia shared common effects on BMD, they have their own effects on BMD independent from each other.

TABLE OF CONTENTS

ABSTRACT

CHAPTER 1. INTRODUCTION

- 1.1 Background
- 1.2 Motivation for the study
- 1.3 Objectives

CHAPTER 2. METHODOLOGY

- 2.1 Participants
- 2.2 Definitions of sarcopenia, osteoporosis and Vitamin D deficiency
- 2.3 Statistical analysis

CHAPTER 3. PRESENTATION OF RESULTS

- 3.1 General characteristics of study populataion
- 3.2 Correlation among serum Vitamin D, appendicular skeletal muscle mass and BMD.
- 3.3Influence of Vitamin D on sarcopenia
- 3.4 The risk for osteoporosis according to vitamin D deficiency and Sarcopenia

CHAPTER 4. SUMMARY, DISCUSSION AND CONCLUSION


4.1 Summary of findings

4.2 Discussion

4.3 Conclusion

REFERENCES

ACKNOWLEDGEMENTS



CHAPTER 1. INTRODUCTION

1.1 Background

A osteoporotic fracture has become a global health issue that causes a tremendous impact on mortality as well as a heavy socioeconomic burden. The estimated number of new osteoporotic fractures for the year 2000 was 9.0 million and fracture sufferers were estimated at 56 million worldwide, [1] Osteoporotic hip fractures cause the most morbidity with reported mortality rates up to 20-24% in the first year after a fracture, and greater risk of death persists for at least 5 years afterwards. Osteoporosis in Europe also contributed to a higher burden than the common neoplastic disorders, save only for lung cancer.[2] In 2004, the estimated cost of treating patients hospitalized with a diagnosis of osteoporosis was \$19.1 billion

Vitamin D is an essential hormone for absorption of calcium in intestine and mineralization of bone. Lips P et al. (2001) showed that inadequate serum vitamin D concentration leads to insufficient mineralization of bone and results in osteomalacia and osteoporosis. [3] The National Health and Nutrition Examination Survey (NHANES) showed that bone mineral density (BMD) correlates positively with 25-hydroxy vitamin D (25(OH) D) concentration in Caucasian women. [4] Vitamin D also reportedly has positive effects on skeletal muscle and strength. Several studies insinuated that vitamin D may influence BMD via its beneficial effects on skeletal muscle. [8,9] Several studies have shown a positive relationship between lean mass and BMD.[5, 6] Women with osteoporosis showed significantly lower appendicular skeletal muscle mass, relative to age-matched controls without osteoporosis.[7]

1.2 Objectives

The purpose of the study is to determine that the positive influence of vitamin D on BMD depends on its beneficial effects on muscle mass.

CHAPTER 2. METHODOLOGY

2.1 Study Participants

This study is based upon the data acquired during the second year (2009) of KNHANES IV, cross-sectional and nationally representative survey conducted by the Division of Chronic Disease Surveillance, Korea Centers for Disease Control and Prevention. Data were collected via household interviews and direct standardized physical examinations conducted in specially equipped mobile examination centers.

The sampling frame was developed based on the 2005 population and housing census in Korea. Household units were selected by a stratified multistage probability sampling design. Two hundred national districts from primary sampling units were randomly sampled, in 2009. Finally, 10078 participated in the health interviews and health examination surveys. We combined the data collected from 7920 participants of KNHANES (ALL) and 8320 participants of KHNANES (DXA) in this study. Among them 3820 women older than 20 years were selected. Premenopausal women who are free from osteoporosis treatment, renal failure and any type of cancer were determined as reference population.

2.2 Definition of osteoporosis, sarcopenia and vitamin D deficiency

DXA (Hologic Discovery-W; Hologic) was used for the measurement of bone mineral density and appendicular muscle mass of the participants.

We use WHO definition, BMD value of 2.5 standard deviation or more below mean for normal young adult or t score of -2.5 to be defined as osteoporosis. Those less than but not reaching -2.5 standard deviation is regarded as osteopenia.

Appendicular Skeletal Mass (ASM) was calculated as the sum of muscle mass in arms and legs, assuming that all nonfat and non-bone tissue is skeletal muscle. Weight-adjusted ASM (total ASM divided by weight x 100) and height adjusted ASM (total ASM divided by height squared) [10]. The calculated weight adjusted ASM value between mean value (28.05%) and 2 standard deviation (24.23%) of reference population is regarded as type 1 sarcopenia and below the 2 standard deviation value is regarded as type 2 sarcopenia (Jansen et. al and Lim et. al).

Serum 25(OH)D levels were measured using a gamma counter (1470 Wizard, Perkin-Elmer) with an radio immunoassay (DiaSorin, Still- water, MN) 25-hydroxyvitamin D (25(OH) D) level between 10-20 ng per milliliter (25nmol per liter) is considered insufficient and below 10ng/dl is considered deficient in Korean population. (Y.-C Hwang et al: Optimal 25-hydroxyvitamin D level for bone (2012)) [11]

2.3 Statistical analysis

Statistical analyses were performed using SPSS software for Mac version 19.0 (SPSS Inc., Chicago, IL). The mean value and standard deviations of gender specific baseline characteristics (age, weight, height, BMI), and body composition including bone mineral density (total, femur, hip, lumbar) were done. Groups of BMDs, vitamin D and weight-adjusted muscle were formed according to cut-off values. The mean and standard deviation values were grouped into 2 and compared according to sarcopenia status by independent T test. The bivariate correlation and partial correlation after adjusting age and BMI, menstrual status moderate exercise and calcium intake among the bone mineral densities, vitamin D, and weight adjusted muscle mass were tested. The odd ratios of sarcopenia and vitamin D deficiency on bone mineral density(BMD) and Vitamin D deficiency on BMD, unadjusted and adjusted for multiple levels were analyzed by logistic regression tests.



CHAPTER 3. PRESENTATION OF RESULTS

3.1 General characteristics of study population

3820 women from age 20 to 91 were included for the analyses. Sarcopenic women were older, shorter in height, and more overweighted than non sarcopenic women. Sarcopenic group had less muscle mass and more fat mass than non-sarcopenic group before and after adjusted for weight or height. Vitamin D concentration and BMD were lower in sarcopenic women, compared to the non-sarcopenic. Daily protein intake was less in sarcopenic group than in non-sarcopenic group while calcium intake did not differ between groups.

Table 1. Demographic characteristics of study subjects

	(Mean ± SD)	
	Non- sarcopenic Women (n=3642)	Sarcopenic women (n=178)
Age	48.7 ±16.0	60.5±14.5**
Height (cm)	156.6 ±6.5	150.8±5.9**
Weight (kg)	56.4 ±87.5	62.8±10.8**
BMI (kg/m ²)	23.0 ±3.2	27.6±4.1**
total fat (g)	18291.18±5028.62	26546.77±5951.63**
Total fat percentage (%)	32.0 ±4.9	42.0±3.5**
ASM (g)	15911.34 ±2496.60	15293.83 ±2218.34**
Weight adjusted ASM (%)	27.8±2.4	21.9±1.4**
Height adjusted ASM (Kg/m ²)	0.6087±0.1046	0.4738±0.2746**
Vitamin D (ng/ml)	17.2 ±6.3	16.0 ±6.2*
Whole body BMD (g/cm ²)	1.091±0.136	1.046±1.350**
Lumar spine L1-4 BMD (g/cm ²)	0.903±0.160	0.874±0.152*
Femoral neck BMD (g/cm ²)	0.701±0.129	0.651±0.138**
Total femur BMD (g/cm ²)	0.853±0.132	0.813±0.139**
Daily protein intake (g)	55.8±27.9	45.8±22.5**
Daily calcium intake (g)	436.69±246.09	380.23±249.133
Moderate exercise (%)	14.3	12.9

** : P value <0.01

*: P value <0.05

BMI : Body mass index

BMD : Bone mineral density

ASM : Appendicular skeletal muscle mass

3.2 Correlation among serum Vitamin D, appendicular skeletal muscle mass and BMD.

In bivariate correlation, vitamin D positively correlated only with height adjusted ASM, not with weight adjusted ASM before and after adjusted for age, menstrual status, daily calcium intake and moderate exercise. Though vitamin D concentration did not show a correlation with femoral BMDs and even negative correlation with lumbar BMD in unadjusted model, after the adjustment, vitamin D had weak but significant correlations with femoral neck and total femur BMD while negative correlation between vitamin D and lumbar BMD disappeared. Weight adjusted and height adjusted ASM had significant positive correlations with all BMDs. Strength of correlation between any BMDs and height adjusted ASM was greater than that between the BMDs and weight adjusted ASM.

Table 2. Bivariate Correlations among vitamin D, appendicular skeletal muscle mass and BMDs at various sites.

		Vitamin D	Weight Adjusted ASM	Height Adjusted ASM	Whole body BMD	Lumbar spine BMD	Femoral Neck BMD	Total Femur BMD
Vitamin D	unadjusted		-0.010	0.048**	-0.008	-0.037**	-0.021	0.020
	Adjusted		0.039	0.056*	0.060	0.042	0.066**	0.093**
Weight adjusted ASM	unadjusted			0.094**	0.076**	0.033**	0.066**	0.014**
	adjusted			0.644**	0.124**	0.024	0.082**	0.048*
Height Adjusted ASM	unadjusted				0.163**	0.187**	0.218**	0.267**
	adjusted				0.197**	0.216**	0.246**	0.316**
Wholebody BMD	unadjusted					0.527**	0.495**	0.495**
	adjusted					0.657**	0.602**	0.596**
Lumbar spine BMD	unadjusted						0.542**	0.537**
	adjusted						0.640**	0.662**
Femoral Neck BMD	unadjusted							0.699**
	adjusted							0.859**
Total Femur BMD	unadjusted							
	adjusted							

** : P value <0.01

• : P value <0.05

BMD : Bone mineral density

ASM : Appendicular skeletal muscle mass

Adjusted : age, menstrual status, daily calcium intake and moderate exercise.

3.3 Influence of Vitamin D on sarcopenia

Woman with vitamin D deficiency had 2.57 times greater odds ratio for type 2 sarcopenia, compared with woman with sufficient vitamin D level. After adjusted for the multiple variables, the odd ratio went up to 4.72 times. Though vitamin D insufficiency had no significant effect on sarcopenia in unadjusted and multiple variables adjusted model, it did show trend for sarcopenia

Table 3. Unadjusted and adjusted odds ratio of vitamin D deficiency for sarcopenia.

		Vitamin D level		
		Sufficiency >20 ng/ml (26.7%)	Insufficiency 10-20 ng/ml (63.6%)	Deficiency <10 ng/ml (9.7%)
Odds Ratio for type 2 sarcopenia	Model 1	1 (ref)	1.41 (0.84 – 2.37)	2.57** (1.34 – 5.02)
	Model 2	1 (ref)	1.762* (1.02 – 3.04)	3.90** (1.89 – 8.05)
	Model 3	1 (ref)	1.79 (0.92 - 3.45)	4.72** (2.01 – 11.1)

95% confidence interval was presented in the brackets

Ref : Reference group

** : P value <0.01

• : P value <0.05

Model 1: Unadjusted

Model 2: Adjusted age and BMI

Model 3: Adjusted age, BMI, menstrual status, calcium intake and moderate exercise

3.4 The risk for osteoporosis according to vitamin D deficiency and Sarcopenia

In unadjusted model, relative to women with sufficient vitamin D, women with neither vitamin D insufficiency nor deficiency did not show significant odd ratio for osteoporosis at any site except femoral neck in vitamin D insufficient group. However after adjusted age, BMI, menstrual status, calcium intake and moderate exercise, odds ratios for osteoporosis at femoral neck and total femur became significant in women with vitamin D deficiency.

After adjusted for height adjusted ASM as well as other variables, odds ratios remained significant at femoral neck and showed same trend at total femur. Vitamin D insufficiency or deficiency did not show effects on lumbar BMD in any model.

Table 4. Unadjusted and adjusted odds ratios for osteoporosis in groups with different vitamin D concentration.

		Vitamin D level		
		Sufficient N = 1068	Insufficient N = 2383	Deficient N = 369
Lumbar spine L1-4 osteoporosis	Model 1	1 (ref)	0.77 (0.50 – 1.18)	0.72 (0.34 – 1.52)
	Model 2	1 (ref)	1.22 (0.77 – 1.94)	0.99 (0.44 – 2.23)
	Model 3	1 (ref)	1.27 (0.78 – 2.06)	1.05 (0.45 – 2.45)
	Model 4	1 (ref)	1.26 (0.78 – 2.04)	1.01 (0.43 – 2.37)
Femoral neck osteoporosis	Model 1	1 (ref)	0.58** (0.42 – 0.81)	1.06 (0.65 – 1.71)
	Model 2	1 (ref)	0.92 (0.63 – 1.36)	2.02* (1.11 – 3.70)
	Model 3	1 (ref)	0.99 (0.66 – 1.48)	2.16* (1.13 – 4.12)
	Model 4	1 (ref)	0.98 (0.65 – 1.46)	2.05* (1.07 – 3.92)
Total Femur osteoporosis	Model 1	1 (ref)	0.74 (0.51 – 1.09)	1.24 (0.72 – 2.15)
	Model 2	1 (ref)	1.25 (0.81 – 1.93)	2.14* (1.10 – 4.18)
	Model 3	1 (ref)	1.25 (0.79 – 1.97)	2.19* (1.09 – 4.45)
	Model 4	1 (ref)	1.23 (0.78 – 1.94)	2.01 (1.00 – 4.08)

95% confidence interval was presented in the brackets

Ref : Reference group

** : P value <0.01

• : P value <0.05

Model 1: Unadjusted

Model 2: Adjusted for age and BMI

Model 3: Adjusted for age, BMI, menstrual status, calcium intake and moderate exercise

Model 4: Adjusted for age, BMI, menstrual status, calcium intake and moderate exercise and weight adjusted ASM

Before adjustment, the odds ratios for osteoporosis at total femur and femoral neck in type 2 sarcopenia were 2.25 and 2.15 respectively, compared with normal muscle group. After adjustment for the multiple variables, the odd ratios were 2.71 and 4.29 respectively in type 2 sarcopenia. Even after adjusted for Vitamin D concentration, the relationship between sarcopenia and osteoporosis remained significant. Type 1 sarcopenia showed similar trends with type 2 sarcopenia. Both type 1 and type 2 sarcopenia did not show any effects on lumbar BMD.

Table 5. Unadjusted and adjusted odds ratios for osteoporosis in groups classified by weight adjusted ASM

		Weight adjusted muscle mass		
		Normal >28.05% N = 1512	Type 1 sarcopenia 24.23 – 28.05% N = 1911	Type 2 sarcopenia <24.23 % N = 397
Osteoporosis at Lumbar spine	Model 1	1 (ref)	1.46 (0.93 – 2.29)	1.51 (0.73 – 3.12)
	Model 2	1 (ref)	1.46 (0.85 – 2.49)	1.35 (0.57 – 3.22)
	Model 3	1 (ref)	1.51 (0.85 – 2.69)	1.66 (0.67 – 4.10)
	Model 4	1 (ref)	1.50 (0.61 – 3.74)	1.51 (0.84 – 2.67)
Osteoporosis at Femoral Neck	Model 1	1 (ref)	1.38* (1.01 – 1.92)	2.25* (1.41 – 3.58)
	Model 2	1 (ref)	1.61* (1.05 – 2.47)	3.18** (1.66 – 6.09)
	Model 3	1 (ref)	1.56 (1.00 – 2.43)	2.71** (1.35 – 5.41)
	Model 4	1 (ref)	1.57* (1.01 – 2.45)	2.59** (1.29 – 5.21)
Osteoporosis at total femur	Model 1	1 (ref)	1.21 (0.84 – 1.75)	2.15* (1.29 – 3.60)
	Model 2	1 (ref)	1.66* (1.04 – 2.65)	4.10** (2.03 – 8.29)
	Model 3	1 (ref)	1.70* (1.04 – 2.79)	4.29** (2.03 – 9.05)
	Model 4	1 (ref)	1.72* (1.05 – 2.81)	3.96** (1.87 – 8.39)

95% confidence interval was presented in the brackets

Ref : Reference group

** : P value <0.01

• : P value <0.05

Model 1: Unadjusted

Model 2: adjusted for age and BMI

Model 3: adjusted for age, BMI, menstrual status, calcium intake and moderate exercise

Model 4: adjusted for age, BMI, menstrual status, calcium intake and moderate exercise and Vitamin D concentration

CHAPTER 4. SUMMARY, DISCUSSION AND CONCLUSION

4.1 Summary of Findings

Both vitamin D concentration and muscle mass positively correlated with BMDs at femoral neck and total femur, but not at lumbar spine. Compared with women with sufficient vitamin D concentration, women with vitamin D deficiency were more than 2 times likelihood to have osteoporosis at femoral neck and total femur, independent of influence from muscle mass. Sarcopenia also had negative impact on BMD like vitamin D deficiency and sarcopenia also has independent effects from vitamin D.

4.2 Discussion

In consistent with our study, a number of cross-sectional studies including Rancho Bernardo's study have reported that serum concentrations of vitamin D were positively related to bone density at proximal femur in the elderly. [12,13] A study [14] including middle-aged women also reported similar relationship between vitamin D concentration and femoral BMD. Supplementation of vitamin D3 for two years in combination with calcium was reported a significant reduction in hip fractures among community dwelling population, resulting in 33% lower rate for osteoporotic fracture and a 22% lower rate for first fracture at any site compared to placebo [15].

Bischoff Ferrari study [16] suggested that positive association of serum vitamin D concentration and BMD may be greater in the 90–100 nmol/L (36 - 40 ng/L) serum range of vitamin D. Our study indicated that the sufficient level of Vitamin D for BMD can be just above 20 ng/ml in Korean population which is pretty lower than in Caucasian population.

Cross-sectional studies showed a positive relationship between vitamin D concentration and muscle mass with aging. In a previous study based on KHNANES, elder Korean men and women with sarcopenia showed lower 25(OH) D levels, regardless of BMI [17]. The longitudinal aging study Amsterdam reported that low vitamin D is associated with loss of muscle mass and strength. [18]

Vitamin D has beneficial effects on BMD through promoting muscle mass and contractibility. Vitamin D receptor is expressed not only in osteoblast [19] but also in myoblast [20]. *In vitro* evidence has demonstrated that vitamin D increases protein synthesis in myoblast and facilitates differentiation of myoblast, resulting in increase in size and number of type 2 muscle fibers [21]. In combination with co-factors "retinoid X receptor" and "Steroid Receptor Coactivator 3" (SRC), the VDR: 1,25(OH)₂vitamin D modulates gene expression of a number of proteins, via binding to specific target gene promoter regions, known as "vitamin D response elements" (VDRE) [22, 23] results in enhanced transcription of a range of proteins. Calbindin [24], one of proteins induced by vitamin D, plays a role in regulating the membrane calcium channel in skeletal muscle for contractile function, which promotes bone formation. The other is insulin-like growth factor binding protein 3 (IGFBP-3) [22] regulates action of insulin like growth factor 1 (IGF-1) that not only stimulates terminal differentiation of muscle cells into myotubes but also promotes stem-cell mediated muscle regeneration and hypertrophy of skeletal muscle. Lean body mass may protect against bone loss, provides greater mechanical loads and stresses than the axial spine through muscular

contraction. Muscle contraction stimulates periosteal apposition, which can also be directly induced by mechanical strain through mechanoreceptors in osteocytes.[25, 26].The beneficial effects of vitamin D on muscle may be explained by moderating secondary hyperparathyroidism which induce atrophy of type 2 muscle fibres in animal models [27]

The Michigan Bone Health Study reported that decreased BMD at the proximal femur could be attributed to premenopausal muscle loss in proximal thigh[28].Another study showed that postmenopausal women with sarcopenia had lower BMD in the femoral neck and total femur. A 12-year longitudinal study [29] showed that reduction in lean body mass contributes to decline in proximal femur BMD. Lean mass is the strongest predictor of cortical bone mineral content of the femur in postmenopausal women [30]but not in the lumbar area. [31]Osteophyticcalcification found in degenerative spondylosis and vascular calcification, usually at the aorta and its major branches can interfere with the interpretation of lumbar BMD and mask the relationship between vitamin D and lumbar spine. [32]. In postmenopausal women the rate of change of bone mineral density, especially at the lumbar spine, may be related to VDR allelic polymorphisms. [33]Observing the change of lumbar-spine bone mineral density over 18 months in 72 elderly subjects, 9 BB homozygotes lost bone mineral density but 26 homozygotes for the alternative genotype (bb) did not (mean change -2.3 [SE 1.0] vs 0.9 [0.7]% per year, $p < 0.05$), irrespective of calcium intake. The lumbar BMD in the genotype (bb) 26 homozygotes did not decrease (mean change -2.3 [SE10] vs 0.9 [0.7]% per year, $p < 0.05$), irrespective of calcium intake. [34] Lumbar vertebrae, which consist primarily of cancellous bone, are more affected by estrogen levels than the femur. In contrast, the femur contains more cortical bone, and has a lower metabolic rate than trabecular bones.

Vitamin D affects bone formation through stimulating osteoblasts differentiation and suppressing osteoblast apoptosis, which is not related with muscle mass.Vitamin D deficiency causes secondary hyperparathyroidism that increases bone resorption leading to decline in BMD. [34] The cytokines IL-1, IL-6 and TNF- α have been shown to regulate bone [35] and evidence from animal models has suggested that cytokines are associated with the development of osteoporosis [36,37] through stimulation of osteoclastogenesis and subsequent bone resorption [38]. Vitamin D level had been more consistently associated with hip BMD than lumbar BMD. [39] Similar results were obtained in a previous study based on KHNANES 2009 -2010 [40]

KHNANESIV is a largepopulation-based National wide study, which can increase the statistical reliability of the results. There is only one ethnicity in our study that we can prevent bias originated from diverse ethnicity. The results of our study were adjusted by the body compositions measured by DXA, that has a privilege in accuracy.

Our study has few limitations.The cross-sectional design in our study is one of them. We did not include the function of skeletal muscle such as strength. However muscle strength well correlates with muscle mass and age which we included in the adjustment.

4.3 Conclusion

Though vitamin D and muscle mass share beneficial effects on bone mineral density, they have independent influence from each other on BMD

Reference

1. Cooper C, Campion G, Melton LJ 3rd. Hip fractures in the elderly: a worldwide projection. *Osteoporos Int*. 1992 Nov;2(6):285-9
2. O. Jonell. J. A Kanis An estimate of the worldwide prevalence and disability associated with osteoporotic fractures: *Osteoporosis Int* (2006) 17:1726-1733
3. Lips, P. Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. *Endocrinology. Rev.* **2001**, 22, 477-501.
4. Eamon Laird, Mary Ward. Vitamin D and Bone Health; Potential Mechanisms. *Nutrients* 2010, 2, 693-724;doi:10.3390/nu2070693.
5. Bakker I, Twisk JW, Van Mechelen W, Kemper HC (2003) Fat-free body mass is the most important body composition determinant of 10-year longitudinal development of lumbar bone in adult men and women. *J ClinEndocrinolMetab* 88:2607–2613
6. Blain H, Vuillemin A, Teissier A, Hanesse B, Guillemin F, Jeandel C (2001) Influence of muscle strength and body weight and composition on regional bone mineral density in healthy women aged 60 years and over. *Gerontology* 47:207–212.
7. Marianne C. Walsh & Gary R. Hunter Margaret Barbara Livingstone Sarcopenia in premenopausal and postmenopausal women with osteopenia, osteoporosis and normal bone mineral density
8. Sato, Y.; Iwamoto, J.; Kanoko, T.; Satoh, K. Low-Dose Vitamin D Prevents Muscular Atrophy and Reduces Falls and Hip Fractures in Women after Stroke: A Randomized Controlled Trial. *Cerebrovasc. Dis.* **2005**, 20, 187-192.
9. Gerdhem, P.; Ringsberg, K.A.M.; Obrant, K.J.; Akesson, K. Association between 25-hydroxy vitamin D levels, physical activity, muscle strength and fractures in the prospective population-based OPRA study of elderly women. *Osteoporos. Int.* **2005**, 16, 1425-1431.
10. Janssen I, Heymsfield SB, Ross R. Low relative skeletal muscle mass (sarcopenia) in older persons is associated with functional impairment and physical disability. *J Am Geriatr Soc.* 2002;50:889–896.
11. Hwang YC, et al. Optimal serum concentration of 25-hydroxyvitamin D for bone health in older Korean adults *Calcif Tissue Int.* 2013 Jan;92(1):68-74. doi: 10.1007/s00223-012-9669-3. Epub 2012 Nov 20.
12. Saquib N, von Muhlen D, Garland CF, Barrett-Connor E (2006) Serum 25-hydroxyvitamin D, parathyroid hormone, and bone mineral density in men: the Rancho Bernardo study. *OsteoporosInt* 17:1734–1741.
13. Von Muhlen DG, Greendale GA, Garland CF, Wan L, Barrett-Connor E (2005) Vitamin D, parathyroid hormone levels and bone mineral density in community-dwelling older women: the Rancho Bernardo Study. *OsteoporosInt* 16:1721–1726
14. Khaw, K.T.; Sneyd, M.J.; Compston, J. Bone density, parathyroid hormone and 25-hydroxyvitamin D concentrations in middle-aged women. *Br. Med. J.* **1992**, 305, 273-277.
15. Trivedi, D.P.; Doll, R.; Khaw, K.T. Effect of four monthly oral vitamin D3 [cholecalciferol] supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. *BMJ* **2003**, 326, 469
16. Bischoff-Ferrari, H.A.; Dietrich, T.; Orav, E.J.; Dawson-Hughes, B. Positive association between 25-hydroxy vitamin D levels and bone mineral density: a population-based study of younger and older adults. *Am. J. Med.* **2004**, 116, 634-639.
17. Kim MK, Baek KH, Song KH, Il Kang M, Park CY, Lee WY, Oh KW (2011) Vitamin D deficiency is associated with sarcopenia in older Koreans, regardless of obesity: the Fourth Korea National Health and Nutrition Examination Surveys (KNHANES IV) 2009. *J ClinEndocrinolMetab* 96:3250–3256

18. MARJOLEIN VISSER, DORLY J. H. DEEG, AND PAUL LIPS (2003) Low Vitamin D and High Parathyroid Hormone Levels as Determinants of Loss of Muscle Strength and Muscle Mass (Sarcopenia): The Longitudinal Aging Study Amsterdam. *The Journal of Clinical Endocrinology & Metabolism* 88(12):5766–5772
19. Costa, E.M.; Blau, H.M.; Feldman, D. 1,25-dihydroxyvitamin D3 receptors and hormonal responses in cloned human skeletal muscle cells. *Endocrinology* **1986**, 119, 2214-2220.
20. Simpson, R.U.; Thomas, G.A.; Arnold, A.J. Identification of 1,25-dihydroxyvitamin D3 receptors and activities in muscle. *J. Biol. Chem.* **1985**, 260, 8882-8891.
21. Sorensen, O.H.; Lund, B.; Saltin, B.; Lund, B.; Andersen, R.B.; Hjorth, L.; Melsen, F.; Mosekilde, L. Myopathy in bone loss of ageing: improvement by treatment with 1 alpha-hydroxycholecalciferol and calcium. *Clin. Sci. (Lond)*. **1979**, 56, 157-161. 22. Peng L, Malloy P, Feldman D. Identification of a functional vitamin d response element in the human insulin-like growth factor binding protein-3 promoter. *MolEndocrinol* 2004; 18: 1109–1119.
23. Liao L, Chen X, Wang S, Parlow A, Xu J. Steroid receptor coactivator 3 maintains circulating insulin-like growth factor 1 (IGF-1) by controlling IGF-binding protein 3 expression. *Mol Cell Biol* 2008; 28: 2460–2469.
24. Fleet J. Rapid, membrane-initiated actions of 1,25 dihydroxyvitamin D: what are they and what do they mean? *J Nutr* 2004; 134: 3215–3218.
25. Petit MA, Beck TJ, Lin HM, Bentley C, Legro RS, Lloyd T (2004) Femoral bone structural geometry adapts to mechanical loading and is influenced by sex steroids: the Penn State Young Women's Health Study. *Bone* 35:750–759.
26. Frost HM (1987) The mechanostat: a proposed pathogenic mechanism of osteoporoses and the bone mass effects of mechanical and nonmechanical agents. *Bone Miner* 2:73–85.
27. Garber, A.J. Effects of parathyroid hormone on skeletal muscle protein and amino acid metabolism in the rat. *J. Clin. Invest.* **1983**, 71, 1806-1821.
28. Sowers M, Crutchfield M, Bandekar R, Randolph JF, Shapiro B, Schork MA, Jannausch M (1998) Bone mineral density and its change in pre- and perimenopausal white women: the Michigan Bone Health Study. *J of Bone and Mineral Res* 13:1134–1140.
29. Liu-Ambrose T, Kravetsky L, Bailey D, Sherar L, Mundt C, Baxter-Jones A, Khan KM, McKay HA (2006) Change in lean body mass is a major determinant of change in areal bone mineral density of the proximal femur: a 12-year observational study. *Calcif Tissue Int* 79:145–151
30. Schoffl I, Kemmler W, Kladny B, Vonstengel S, Kalender WA, Engelke K (2008) In healthy elderly postmenopausal women variations in BMD and BMC at various skeletal sites are associated with differences in weight and lean body mass rather than by variations in habitual physical activity, strength or VO2max. *J Musculoskelet Neuronal Interact* 8:363–374
31. Petit MA, Beck TJ, Lin HM, Bentley C, Legro RS, Lloyd T (2004) Femoral bone structural geometry adapts to mechanical loading and is influenced by sex steroids: the Penn State Young Women's Health Study. *Bone* 35:750–759
32. Morrison NA, Qi J-C, Tokita A, et al. Prediction of bone density by vitamin D receptor alleles. *Nature* 1994; 367: 284-87.
33. S Ferrari, R Rizzoli, Vitamin D receptor gene polymorphisms and change in lumbar spine bone mineral density, *Lancet* 1995; 345: 423-24.
34. Montero-Odasso M, Duque G (2005) Vitamin D in the aging musculoskeletal system: an authentic strength preserving hormone. *Mol Aspects Med* 26:203–219.
35. Muller, K.; Haahr, P.M.; Diamant, M. 1,25-Dihydroxyvitamin D3 inhibits cytokine production by human blood monocytes at the post-transcriptional level. *Cytokine* **1992**, 4, 506-512.
36. Evans, K.N.; Nguyen, L.; Chan, J.; Innes, B.A.; Bulmer, J.N.; Kilby, M.D.; Hewison, M. Effects of 25-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 on cytokine production by human decidual cells. *Biol. Reprod.* **2006**, 75, 816-822.
37. Zhu, Y.; Mahon, B.D.; Froicu, M.; Cantorna, M.T. Calcium and 1 alpha,25-dihydroxyvitamin D3 target the TNF-alpha pathway to suppress experimental inflammatory bowel disease. *Eur. J. Immunol.* **2005**, 35, 217-224

38. Bendixen A.C.; Shevde N.K.; Dienger K.M.; Willson T.M.; Funk C.D.; Pike J.W. *IL-4 inhibits osteoclast formation through a direct action on osteoclast precursors via peroxisome proliferator-activated receptor gamma 1*. Proc. Natl. Acad. Sci. USA **2001**, *98*, 2443-2448.

39. Binkley N (2012) *Vitamin D and osteoporosis-related fracture*. Arch BiochemBiophys *523*:115–122

40. S.-G.Lee & Y.-h.Lee & K.J.Kim & W.Lee & O.H.Kwon & J.-H. Kim *Additive association of vitamin D insufficiency and sarcopenia with low femoral bone mineral density in noninstitutionalized elderly population: the Korea National Health and Nutrition Examination Surveys 2009–2010* Osteoporos Int DOI 10.1007/s00198-013-2378-6

ACKNOWLEDGEMENTS

First of all, I would like to say thank you to my supervisor Professor BomTaeck Kim (MD. Phd) for supporting me with all his efforts for this study and taking care throughout my stay at AjouUniversity and my two other supervisors Professor Bak and Professor Ann. Next, I would like to pay my gratitude to Professor Nam SeokJoo, for giving me advice on statistical analysis and Dr.YoungSang Kim for providing me with KHNANES data and sources. Then, I would like to thank Professor Eu Young Soh (M.D, Phd) for giving me such a great opportunity to attend this university, the director and the former director of Family Medicine department, Professor Kang Min Kim (MD. Phd.) and Professor Duck Joo Lee (MD. Phd.) for the warmth given to me during my practice in Family Medicine department. I am also grateful to meet Miss Woo from Academic office who helps me with all the administration works. The last but not least, I would like to pay gratitude to my family, my fiancé, and my friends for giving me emotional support during hard times.